Vaxcell-Bio Therapeutics Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
86
- Stock Symbol
-
323990
- Investments
-
4
- Share Price
-
$2.79
- (As of Thursday Closing)
Vaxcell-Bio Therapeutics General Information
Description
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.
Contact Information
Website
www.vaxcell-bio.comCorporate Office
- 98-1 Sandan-gil
- Hwasun-eup
- Hwasun-gun, Jeollanam-do 58141
- South Korea
Corporate Office
- 98-1 Sandan-gil
- Hwasun-eup
- Hwasun-gun, Jeollanam-do 58141
- South Korea
Vaxcell-Bio Therapeutics Stock Performance
As of 19-Nov-2026, Vaxcell-Bio Therapeutics’s stock price is $2.79. Its current market cap is $64.6M with 23.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.79 | $2.73 | $2.32 - $8.05 | $64.6M | 23.2M | 260K | -$0.44 |
Vaxcell-Bio Therapeutics Financials Summary
As of 30-Jun-2026, Vaxcell-Bio Therapeutics has a trailing 12-month revenue of $4.49M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 65,115 | 144,798 | 136,612 | 388,684 |
| Revenue | 4,487 | 4,958 | 1,392 | 10 |
| EBITDA | (9,183) | (8,686) | (8,467) | (8,403) |
| Net Income | (10,279) | (9,374) | (7,786) | (7,858) |
| Total Assets | 38,031 | 46,460 | 52,237 | 65,944 |
| Total Debt | 1,008 | 1,381 | 1,540 | 280 |
Vaxcell-Bio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vaxcell-Bio Therapeutics Patents
Vaxcell-Bio Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026101191-A1 | Novel vascularization inhibitor and use thereof | Pending | 11-Nov-2024 | ||
| WO-2026042913-A1 | Composition for treating cancer in tumor-affected dogs comprising recombinant canine interleukin-15 | Pending | 22-Aug-2024 | ||
| WO-2025254457-A1 | Epcam and cd3-bispecific antibody fragment having affinity-modulated mutant | Pending | 04-Jun-2024 | ||
| WO-2025254456-A1 | Nanobody-scfv antibody fragment bispecific for epcam and cd3 | Pending | 04-Jun-2024 | ||
| WO-2025254458-A1 | Proteasome inhibitor comprising lactone structure | Pending | 04-Jun-2024 |
Vaxcell-Bio Therapeutics Signals
Vaxcell-Bio Therapeutics Investments & Acquisitions (4)
Vaxcell-Bio Therapeutics’s most recent deal was a Later Stage VC with CNCure biotech for . The deal was made on 25-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CNCure biotech | 25-Jun-2026 | Later Stage VC | Drug Discovery | ||
| MetaImmuneTech | 04-Dec-2025 | Seed Round | Diagnostic Equipment | ||
| AL Biotech | 01-Mar-2025 | Merger/Acquisition | Drug Discovery | ||
| SH Pharm | 14-Oct-2024 | Merger/Acquisition | Pharmaceuticals |
Vaxcell-Bio Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.98 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vaxcell-Bio Therapeutics FAQs
-
When was Vaxcell-Bio Therapeutics founded?
Vaxcell-Bio Therapeutics was founded in 2010.
-
Where is Vaxcell-Bio Therapeutics headquartered?
Vaxcell-Bio Therapeutics is headquartered in Hwasun-gun, South Korea.
-
What is the size of Vaxcell-Bio Therapeutics?
Vaxcell-Bio Therapeutics has 86 total employees.
-
What industry is Vaxcell-Bio Therapeutics in?
Vaxcell-Bio Therapeutics’s primary industry is Drug Discovery.
-
Is Vaxcell-Bio Therapeutics a private or public company?
Vaxcell-Bio Therapeutics is a Public company.
-
What is Vaxcell-Bio Therapeutics’s stock symbol?
The ticker symbol for Vaxcell-Bio Therapeutics is 323990.
-
What is the current stock price of Vaxcell-Bio Therapeutics?
As of 19-Nov-2026 the stock price of Vaxcell-Bio Therapeutics is $2.79.
-
What is the current market cap of Vaxcell-Bio Therapeutics?
The current market capitalization of Vaxcell-Bio Therapeutics is $64.6M.
-
What is Vaxcell-Bio Therapeutics’s current revenue?
The trailing twelve month revenue for Vaxcell-Bio Therapeutics is $4.49M.
-
What is Vaxcell-Bio Therapeutics’s annual earnings per share (EPS)?
Vaxcell-Bio Therapeutics’s EPS for 12 months was -$0.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process